Literature DB >> 4830234

On the adaptation in sodium excretion in chronic uremia. The effects of "proportional reduction" of sodium intake.

R W Schmidt, J J Bourgoignie, N S Bricker.   

Abstract

Renal mass and glomerular filtration rate (GFR) were reduced from normal to approximately 15% of normal in two groups of dogs. One group received a constant salt intake (CSI) throughout the study. The second group was subjected to "proportional reduction" of sodium intake (PRS), a dietary regimen which involved the reduction of sodium intake in exact proportion to the decrement in GFR. In the CSI group, absolute sodium excretion rate (U(Na)V) remained essentially unchanged as GFR fell, while fractional sodium excretion (FE(Na)) increased progressively from a mean control value of 0.3% to a final value of 4.4%. In the PRS group, U(Na)V decreased with each reduction in GFR and salt intake, and FE(Na) remained constant throughout. In a second study, the fraction of serum that previously has been shown to possess natriuretic activity in studies of uremic patients was obtained from a group of uremic dogs on the CSI and from another group on the PRS regimen, and the effects of the fraction was measured on sodium excretion in rats. The serum fractions from the dogs on the CSI regimen produced a significant increase in both U(Na)V and FE(Na) in the assay rats. The same serum fraction from the dogs on the PRS regimen failed to produce a significant increase in either U(Na)V or FE(Na). The data are consistent with the view that (a) The increase in FE(Na) in chronically uremic dogs is dictated by the requirements for external sodium balance and may be prevented by prospective manipulation of salt intake: (b) a natriuretic factor, previously shown to exist in the serum of patients with chronic uremia, is also demonstrable in the serum of uremic dogs; and (c) with the present bioassay system, the factor is not detectable in the serum fraction of uremic dogs in which the requirements for an increased natriuresis per nephron have been obviated.

Entities:  

Mesh:

Substances:

Year:  1974        PMID: 4830234      PMCID: PMC302670          DOI: 10.1172/JCI107725

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  7 in total

1.  AUTOMATED AND MANUAL DIRECT METHODS FOR THE DETERMINATION OF BLOOD UREA.

Authors:  W H MARSH; B FINGERHUT; H MILLER
Journal:  Clin Chem       Date:  1965-06       Impact factor: 8.327

2.  On the prevention of secondary hyperparathyroidism in experimental chronic renal disease using "proportional reduction" of dietary phosphorus intake.

Authors:  E Slatopolsky; S Caglar; L Gradowska; J Canterbury; E Reiss; N S Bricker
Journal:  Kidney Int       Date:  1972-09       Impact factor: 10.612

3.  The presence of a natriuretic factor in urine of patients with chronic uremia. The absence of the factor in nephrotic uremic patients.

Authors:  J J Bourgoignie; K H Hwang; E Ipakchi; N S Bricker
Journal:  J Clin Invest       Date:  1974-06       Impact factor: 14.808

4.  Studies on the characteristics of the control system governing sodium excretion in uremic man.

Authors:  E Slatopolsky; I O Elkan; C Weerts; N S Bricker
Journal:  J Clin Invest       Date:  1968-03       Impact factor: 14.808

5.  Studies on the control of sodium excretion in experimental uremia.

Authors:  R G Schultze; H S Shapiro; N S Bricker
Journal:  J Clin Invest       Date:  1969-05       Impact factor: 14.808

6.  A natriuretic factor in the serum of patients with chronic uremia.

Authors:  J J Bourgoignie; K H Hwang; C Espinel; S Klahr; N S Bricker
Journal:  J Clin Invest       Date:  1972-06       Impact factor: 14.808

7.  Inhibition of transepithelial sodium transport in the frog skin by a low molecular weight fraction of uremic serum.

Authors:  J Bourgoignie; S Klahr; N S Bricker
Journal:  J Clin Invest       Date:  1971-02       Impact factor: 14.808

  7 in total
  14 in total

1.  Effects of atrial natriuretic peptide on systemic and renal hemodynamics and renal excretory function in patients with chronic renal failure.

Authors:  H Meyer-Lehnert; T Bayer; H G Predel; K Glänzer; H J Kramer
Journal:  Klin Wochenschr       Date:  1991-11-26

Review 2.  Endogenous cardiotonic steroids: physiology, pharmacology, and novel therapeutic targets.

Authors:  Alexei Y Bagrov; Joseph I Shapiro; Olga V Fedorova
Journal:  Pharmacol Rev       Date:  2009-03       Impact factor: 25.468

Review 3.  Misapplications of commonly used kidney equations: renal physiology in practice.

Authors:  Mai T Nguyen; Sharon E Maynard; Paul L Kimmel
Journal:  Clin J Am Soc Nephrol       Date:  2009-03-04       Impact factor: 8.237

Review 4.  Endogenous cardiotonic steroids in kidney failure: a review and an hypothesis.

Authors:  John M Hamlyn; Paolo Manunta
Journal:  Adv Chronic Kidney Dis       Date:  2015-05       Impact factor: 3.620

5.  Humoral factors and the sodium-potassium pump in low renin hypertension.

Authors:  F J Haddy
Journal:  Klin Wochenschr       Date:  1982-10-01

6.  The approach to the treatment of hypertensive patients with renal parenchymal disease.

Authors:  L U Mailloux; P A Bluestone; R T Mossey
Journal:  Bull N Y Acad Med       Date:  1982-03

7.  Atrial natriuretic peptide and sodium homeostasis in chronic renal failure.

Authors:  T Tulassay; W Rascher; K Schärer
Journal:  Pediatr Nephrol       Date:  1989-10       Impact factor: 3.714

8.  The presence of a natriuretic factor in urine of patients with chronic uremia. The absence of the factor in nephrotic uremic patients.

Authors:  J J Bourgoignie; K H Hwang; E Ipakchi; N S Bricker
Journal:  J Clin Invest       Date:  1974-06       Impact factor: 14.808

9.  Role of atrial natriuretic peptide in adaptation of sodium excretion with reduced renal mass.

Authors:  S Smith; S Anderson; B J Ballermann; B M Brenner
Journal:  J Clin Invest       Date:  1986-04       Impact factor: 14.808

10.  An inhibitor of sodium transport in the urine of dogs with normal renal function.

Authors:  H Favre; K H Hwang; R W Schmidt; N S Bricker; J J Bourgoignie
Journal:  J Clin Invest       Date:  1975-11       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.